Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Pulmotech MAA Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The historical growth was largely a result of the escalating prevalence of pulmonary embolism, alongside the expansion of nuclear medicine units in hospitals, the easy availability of technetium-based radiopharmaceuticals, an uptick in diagnostic imaging volumes, and the growing reliance on lung scintigraphy within clinical practice.
The anticipated expansion during the forecast period is driven by a heightened need for prompt and precise pulmonary diagnostics, along with greater funding for nuclear medicine facilities. It also stems from the broader application of radiotracers in clinical research, an escalating emphasis on tailored diagnostic imaging, and ongoing improvements in imaging agent technology. Key developments expected to shape this period include a growing preference for sophisticated lung perfusion imaging products, increased utilization of nuclear medicine techniques in diagnosing lung conditions, a surge in demand for reliable pulmonary embolism identification, the widening use of radiopharmaceuticals in clinical settings, and a stronger focus on enhancing both the precision and safety of imaging procedures.
Download A Free Sample Report For Comprehensive Market Insights:
#Pulmotech MAA Market Growth Factors: Which Forces Are Supporting Market Expansion?
The anticipated rise in respiratory disease cases is set to foster growth in the pulmotech MAA market in the upcoming period. Respiratory diseases encompass a variety of disorders impacting the lungs and respiratory system, including the airways, lungs, and respiratory muscles. Factors such as environmental pollution, lifestyle choices, aging demographics, and improved diagnostic tools are contributing to the heightened occurrence of these conditions. Pulmotech MAA plays a role in diagnosing and handling chronic respiratory issues through enhanced pulmonary imaging, which evaluates regional lung function and identifies possible abnormalities like perfusion deficits. As an example, data from the Australian Institute of Health and Welfare, a health and welfare body based in Australia, revealed in June 2024 that roughly 8.5 million Australians, representing 34% of the population, were projected to have chronic respiratory conditions. This figure comprised about 2.8 million individuals, or 11% of the population, with asthma, and 638,000 people, or 2.5%, living with chronic obstructive pulmonary disease (COPD). Consequently, the growing frequency of respiratory diseases is fueling demand in the pulmotech MAA market.
The mounting incidence of chronic conditions is anticipated to spur advancement in the pulmotech MAA market moving forward. Chronic diseases are defined as health issues that endure over lengthy durations, frequently spanning years or a lifetime, and their rising prevalence stems mainly from shifts in lifestyle, older population segments, and environmental influences. Pulmotech MAA proves beneficial in addressing the escalating burden of chronic illnesses, especially those impacting the respiratory system. This technology aids in evaluating and handling chronic diseases via precise pulmonary perfusion imaging, which supports diagnosis of conditions like pulmonary embolism and monitoring of lung disorders. For instance, in April 2025, the National Center for Health Statistics (NCHS), part of the US-based Centers for Disease Control and Prevention (CDC), reported a growing trend in chronic diseases, particularly among younger and middle-aged adults. Obesity among young adults increased from 27.3% in 2023, while depression rates climbed from 25.0%, with diabetes and chronic kidney disease also rising in midlife groups. Hence, the expanding prevalence of chronic diseases is projected to propel the pulmotech MAA market forward.
The growth of the pulmotech MAA market in the coming years is expected to be driven by the expanding elderly population. An aging population refers to a demographic trend where the percentage of older individuals, typically those aged 65 and above, increases. This shift is fueled by longer life expectancies resulting from healthcare advancements, enhanced living standards, and more effective management of chronic illnesses. Pulmotech MAA supports this demographic by offering detailed pulmonary imaging for diagnosing and tracking age-related respiratory conditions, which enables timely and precise treatment strategies. For example, statistics from the Population Reference Bureau (PRB), a US-based nonprofit, indicated in January 2024 that the number of Americans aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase, with their share of the total population growing from 17% to 23%. As a result, the expanding aging population is propelling the pulmotech MAA market.
Pulmotech MAA Market Segment Performance And Strategic Opportunities
The pulmotech maa market covered in this report is segmented –
1) By Application: Pulmonary Embolism Diagnosis, Preoperative Assessment, Lung Transplant Viability, Chronic Respiratory Disease Evaluation, Clinical Research
2) By Distribution Channel: Direct Sales, Distributors, Online Platforms
3) By End-User: Hospitals, Research Institutions, Diagnostic Imaging Centers
Pulmotech MAA Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the pulmotech maa market are Curium Pharma
Access The Complete Pulmotech MAA Market Report:
Pulmotech MAA Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the pulmotech MAA market in 2025. The regions covered in the pulmotech maa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model